XML 82 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Licenses (Licenses) | 12 Months Ended
--- | ---
Dec. 31, 2013
Licenses |
Licenses |
Licenses | 8. Licenses
|  | December 31, 2013 |
|  |  |  | Accumulated |  | Net book |
|  | Cost |  | amortization |  | value |
Inactivated hepatitis A |  | 3,490 |  | 3,490 |  | — |
Combined inactivated hepatitis A&B |  | 502 |  | 452 |  | 50 |
H5N1 licenses (note 22) |  | 1,519 |  | 797 |  | 722 |
Total |  | $ | 5,511 |  | $ | 4,739 |  | $ | 772 |
|  | December 31, 2012 |
|  |  |  | Accumulated |  | Net book |
|  | Cost |  | amortization |  | value |
Inactivated hepatitis A |  | 3,391 |  | 3,391 |  | — |
Combined inactivated hepatitis A&B |  | 488 |  | 390 |  | 98 |
H5N1 licenses (note 22) |  | 1,476 |  | 424 |  | 1,052 |
Total |  | $ | 5,355 |  | $ | 4,205 |  | $ | 1,150 |
(a) On August 15, 2011, the Company entered into a non-exclusive main license agreement together with three sublicense agreements with Medimmune, LLC (“Medimmune”) to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. The Company amortized the patent fee on a straight-line method basis over the estimated useful life of 20 years. On August 15, 2012, the Company entered into amendment agreements with Medimmune which amended the term of the license agreements. As for the main license agreement, the estimated useful life of the patent was revised to end on December 29, 2015. The other three sublicense agreements have been revised to end on April 5, 2020, July 14, 2020, and May 23, 2021, respectively. According, the estimated useful life of the patent was revised to end on December 29, 2015 (note 22) which is the termination date of the main license agreement. (b) Amortization expense for the licenses was $268, $228 and $435 for 2011, 2012 and 2013, respectively. (c) Estimated amortization expense for the existing licenses over their remaining useful lives as of December 31, 2013 is as follows:
Within 1 year |  | $ | 411 |
Between 1 and 2 years |  | 361 |
Between 2 and 3 years |  | — |
Total |  | $ | 772 |
The above amortization expense forecast is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, changes in foreign currency exchange rates, impairment of licenses and other events.

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration